Similarly, empagliflozin activates the AMPK/mTOR pathway, upregulates LC3B expression, induces autophagy, and improves NAFLD in apolipoprotein E (ApoE) knockout mouse models (142). This evidence concerns the gene APOE and metabolic dysfunction-associated steatotic liver disease.